Global Brain Tumour Diagnosis and Treatment Market Size, Trend & opportunity Analysis Report, By Product Type (Primary Brain Tumor, Secondary Brain Tumor), By Diagnosis Type (CT scan, MRI, PET-CT scan, Molecular Testing, EEG), By Treatment Type (Surgery, Radiation Therapy, Targeted Therapy, Chemotherapy, Immunotherapy), End User (Hospitals, Ambulatory Surgical Centres) And Forecasts, 2025 -2035
Global Brain Tumour Diagnosis And Treatment Market Size Opportunity Analysis & Forecast,2025-2035
Market Definition and Introduction
The Global Brain Tumor Diagnosis and Treatment Market was valued at USD 1.6 billion in 2024 and is expected to reach USD 2.62 billion by 2035, strong CAGR of 4.6 % from 2025 to 2035. This growth is driven by developing incidences of primary and secondary brain tumors, increasing investments in advanced diagnostic imaging, and rapid developments in targeted and precision therapies. Early detection initiatives, supported by government cancer manage programs and growing patient awareness, are further accelerating adoption rates across healthcare systems worldwide.
Brain tumors comprising malignant and benign lesions such as gliomas, meningiomas, and metastatic brain tumors represent an important global healthcare challenge. Diagnostic modalities, including MRI, PET-CT, liquid biopsies, and molecular testing, play a pivotal role in accurate staging and treatment planning. On the therapeutic front, advancements in neurosurgery, radiation oncology, chemotherapy, immunotherapy, and targeted therapies have expanded treatment options, allowing clinicians to personalise interventions based on tumor genetics and patient-specific factors.
Emerging technologies are creating the neuro-oncology ecosystem. AI-powered imaging algorithms are improving early detection accuracy, while robotic-assisted surgical platforms are improving procedural precision and patient recovery outcomes. The integration of biomarker-driven therapiesand precision oncology tools is revolutionising treatment paradigms, allowing oncologists to design highly tailored therapeutic regimens. With healthcare systems in both developed and improving markets prioritising oncology structure modernisation, the brain tumor diagnosis and treatment market is poised to deliver significant clinical and economic impact over the next decade.
Recent Developments in Industry
- In March 2024, AstraZeneca completed the acquisition of Fusion Pharmaceuticals in March 2024 to strengthen its precision oncology pipeline. This strategic move accelerates the development of targeted radiopharmaceutical therapies for difficult-to-treat cancers, including glioblastoma and metastatic brain tumors. By integrating Fusion’s radioconjugate platform, AstraZeneca aims to deliver next-generation, tumour-specific therapies with improved efficacy and safety profiles compared to conventional chemotherapy and radiotherapy approaches.
- In January 2024, GE HealthCare acquired MIM Software, a heads in AI-powered imaging analytics for oncology and neurology. This acquisition expands GE’s diagnostic imaging capabilities, allowing automated tumour segmentation, treatment planning, and precision radiotherapy workflows. The integration supports healthcare providers with faster, more accurate brain tumour diagnosis and treatment decision-making, improving clinical efficiency across neuro-oncology centres worldwide.
- In February 2024, the U.S. FDA expanded the approved indications for Tumor Treating Fields (TTFields) in February 2024, strengthening its role as a non-invasive treatment modality for aggressive brain tumours such as glioblastoma. Backed by clinical data demonstrating improved survival outcomes and reduced systemic toxicity, TTFields adoption is expected to accelerate across heading neuro-oncology centres in North America and Europe.
- In April 2024, Novocure partnered with Roche to evaluate TTFields in combination with immunotherapy agents for recurrent glioblastoma. This collaboration integrates device-based therapy with immuno-oncology drugs, aiming to improve treatment responses in high-grade brain tumour patients resistant to standard care.
Market Dynamics
Increasing Global Prevalence of Brain Tumors Drives Demand for Advanced Diagnostic Solutions.
The increasing global incidence of primary brain tumors such as gliomas, meningiomas, and metastatic brain lesions is fuelling demand for early detection and precision diagnostic solutions. The widespread use of high-resolution MRI, PET-CT imaging, and AI-powered diagnostic tools enables clinicians to detect tumors at earlier stages, supporting accurate treatment planning and better patient outcomes. Healthcare systems are prioritising early intervention strategies to reduce disease burden and mortality rates.
Breakthrough Immunotherapy and Targeted Treatments Are Expanding Opportunities in Neuro-Oncology Care.
The advent of immune checkpoint inhibitors, therapeutic cancer vaccines, and molecularly targeted agents is transforming treatment protocols for brain tumors. These novel therapies offer higher efficacy with fewer side effects, addressing the toxicity concerns of traditional chemotherapy and radiotherapy. Clinical studies exploring CAR-T cell therapy in glioblastoma signal a new era of personalised, immune-driven neuro-oncology treatments with powerful commercial potential.
High Costs and Limited Infrastructure Hinder Adoption of Advanced Brain Tumor Treatments in Emerging Markets.
Despite rapid technological advancements, high procedural costs, weak reimbursement policies, and healthcare infrastructure limitations hinder the adoption of cutting-edge neuro-oncology solutions in low- and middle-income countries. The uneven distribution of diagnostic imaging facilities and specialist oncology centres continues to widen the treatment gap between developed and developing regions, creating a pressing need for cost-effective care models.
AI Integration and Precision Medicine Investments Are Transforming Competitive Dynamics in Neuro-Oncology.
Significant funding in AI-based imaging analytics, molecular diagnostics, and robotic-assisted neurosurgery is accelerating innovation across neuro-oncology. The convergence of digital health technologies, biomarker-driven therapy selection, and personalised medicine platforms is expected to drive clinical breakthroughs and expand global market accessibility over the next decade.
Global Challenges in Equitable Brain Tumor Care Persist Despite Technological Advancements.
Addressing healthcare disparities, regulatory complexities, and cost barriers remains critical to ensuring equitable access to advanced brain tumor care worldwide. United research, public-private partnerships, and maintainable pricing strategies will play a pivotal role in bridging existing treatment gaps.
Attractive Opportunities in the Market
- Advanced diagnostic accuracy with AI-driven MRI and PET-CT interpretation tools.
- Breakthrough immune checkpoint inhibitors improving glioblastoma treatment outcomes.
- Non-invasive biomarker testing for early detection and monitoring of tumor progression.
- Improved surgical precision and reduced complications in tumor resections.
- Targeted radioisotope treatments are increasing momentum in aggressive tumor types.
- Remote consultations are accelerating access to diagnostic and treatment expertise.
- Global partnerships accelerating novel therapy development and approval timelines.
- Point-of-care imaging expanding access in rural and underserved settings.
Report Segmentation
By Product Type: Primary Brain Tumor, Secondary Brain Tumor
By Product Analysis: Stains and Varnishes, Shellacs, Lacquers, Others
By Diagnosis Type: CT Scan, MRI, PET-CT Scan, Molecular Testing, EEG, Others
By Treatment Type: Surgery, Radiation Therapy, Targeted Therapy, Chemotherapy, Immunotherapy
By End User: Hospitals, Ambulatory Surgical Centres
By Region: North America( U.S., Canada, Mexico), Europe (UK, Germany, France, Spain, Italy, Rest of Europe), Asia-Pacific (China, India, Japan, Australia, South Korea, Rest of Asia-Pacific), LAMEA ( Brazil, Argentina, UAE, Saudi Arabia (KSA), Africa, Rest of Latin America)
Key Players: Merck & Co., Inc., Siemens Healthineers AG, Carestream Health, Hitachi, Ltd. (Japan), Koninklijke Philips N.V. (Netherlands), Shimadzu Corporation (Japan), Canon Medical Systems (Japan), Eisai Co., Ltd. (Japan), Elekta (Sweden), Varian Medical Systems, Inc., FUJIFILM Corporation (Japan), NantOmics, Hologic, Inc., Thermo Fisher Scientific Inc., Genentech, Inc., Bristol-Myers Squibb Company
Report Aspects
- Base Year: 2024
- Historic Years: 2022, 2023, 2024
- Forecast Period: 2025–2035
- Report Pages: 293
Dominating Segments
The Primary Brain Tumor segment dominates the market by product type, with 58.4% global revenue share in 2024.
The primary brain tumor segment, led by rising cases of gliomas and meningiomas, accounted for 58.4% of the global market in 2024. Increasing adoption of early diagnostic screening supported by AI-enabled imaging technologies has accelerated detection rates, ensuring timely interventions and better patient results. Improved awareness campaigns, expanding neuro-oncology infrastructure, and prioritisation of precision diagnostics continue to strengthen this segment’s leading position in both developed and emerging economies.
Stains and Varnishes lead the product analysis segment, securing 54% global revenue contribution in 2024.
Stains and varnishes remain indispensable in the histopathological diagnosis of brain tumors, capturing 54% market share in 2024. Their critical role in improving tissue visualisation and cellular detail underpins their dominance across pathology laboratories. The demand surge is driven by standardisation of diagnostic protocols, increased oncology testing volumes, and growing integration of digital pathology platforms, ensuring accurate and reproducible diagnostic insights for neuro-oncology specialists worldwide.
MRI dominates the diagnostic modality segment with a 34.9% share as the gold standard for brain tumor detection.
Magnetic Resonance Imaging (MRI) continues to lead the diagnostic modality segment, accounting for 34.9% of the market in 2024. Its high-resolution, non-invasive imaging abilities make it indispensable for early tumor detection, surgical planning, and treatment monitoring. Ongoing technological upgrades, such as functional MRI and diffusion tensor imaging, enhance diagnostic accuracy while expanding clinical applications, ensuring MRI’s sustained leadership in neuro-oncology imaging solutions.
The surgery segment holds the largest share among treatment modalities, capturing 36.7% of global revenues in 2024.
Surgery remains the frontline treatment for brain tumors, representing 36.7% of the market in 2024. Advances in minimally invasive neurosurgical techniques, neuronavigation systems, and intraoperative imaging are improving procedural safety, decreasing recovery times, and enhancing clinical outcomes. The growing preference for tumor resection procedures supported by rapid post-surgical rehabilitation reinforces the segment’s dominance across global neuro-oncology markets.
Hospitals dominate the end-user landscape with a 74.5% market share, reflecting integrated oncology care ecosystems.
Hospitals accounted for 74.5% of the end-user market in 2024, driven by access to comprehensive oncology infrastructure and multidisciplinary expertise. Their ability to integrate diagnostics, surgery, radiotherapy, and post-treatment care under one roof ensures optimal patient outcomes. Moreover, hospitals remain the preferred sites for clinical trials, immunotherapy administration, and advanced neurosurgical interventions, sustaining their leadership position across neuro-oncology care delivery networks.
Key Takeaways
- As per the analysis shared by our research analyst, the global brain tumour diagnosis and treatment market is estimated to grow annually at a CAGR of around 4.4% over the forecast period (2025-2035).
- Regarding revenue, the global brain tumour diagnosis and treatment market size was valued at around USD 1.67 billion in 2025 and is projected to reach USD 2.57 billion by 2035.
- Based on Diagnosis, the MRI segment is expected to lead the global market.
- The Surgery segment is growing at a high rate and will continue to dominate the global market.
- The Primary Brain Tumour part is projected to sweep the largest market share.
- North America and Europe are also based on the brain diagnosis and treatment market.
Regional Insights
North America dominates the global brain tumor diagnosis and treatment market with a 40.01% revenue share in 2024.
North America continues to lead the global brain tumor diagnosis and treatment market, accounting for 40.01% revenue share in 2024. The region benefits from cutting-edge healthcare infrastructure, early adoption of AI-enabled imaging technologies, and a robust network of clinical trial centres, leading innovation in neuro-oncology. Favourable reimbursement frameworks across the United States and Canada further enhance patient access to advanced diagnostic modalities and targeted therapies. Strategic collaborations between pharmaceutical giants, academic research institutes, and government agencies accelerate the development of precision medicine approaches, positioning North America as the innovation hub for brain tumour diagnosis, treatment, and clinical research leadership worldwide.
Europe registers steady growth through precision diagnostics, advanced radiation therapies, and government cancer care initiatives.
Europe witnesses significant growth driven by NHS-backed early detection programmes in the UK, expanding oncology research pipelines in Germany, and increasing healthcare investments across France and Italy. The adoption of high-resolution MRI and PET-CT platforms for early tumour detection, alongside integration of proton beam therapies and robot-assisted surgical systems, strengthens Europe’s clinical abilities in brain tumour management. EU-wide funding programmes support collaborative research initiatives, while regulatory bodies expedite approvals for innovative therapeutics, allowing faster patient access. Collectively, these elements ensure Europe maintains a competitive place in precision diagnostics and advanced neuro-oncology treatments within the global market landscape.
Asia-Pacific emerges as the fastest-growing market with an 8.7% CAGR, driven by healthcare infrastructure expansion.
The Asia-Pacific region records the highest forecasted CAGR of 8.7% through 2035, powered by rising investments in healthcare infrastructure, government-led cancer screening initiatives, and AI integration in radiology platforms across China, India, and Japan. Large patient populations and increasing awareness about early tumour detection propel diagnostic adoption, while collaborations between global medtech firms and regional healthcare providers boost access to targeted therapies. Technological advancements in telemedicine and robotic neurosurgery expand treatment reach beyond major metropolitan centres, ensuring better healthcare equity. Combined with growing clinical trial activities, these factors solidify Asia-Pacific’s position as the fastest-growing hub for brain tumour diagnostics and treatment advancement.
The LAMEA region unlocks new growth opportunities with rising cancer burden and healthcare modernisation initiatives.
The LAMEA region, encompassing Latin America, the Middle East, and Africa, shows promising growth potential with expanding oncology centres, adoption of tele-radiology platforms, and increasing government investments in public-private healthcare partnerships. Countries such as Brazil, the UAE, and South Africa focus on strengthening diagnostic abilities and launching national cancer care initiatives to address the rising cancer burden. Technological collaborations with international medtech companies introduce AI-enabled imaging solutions and affordable diagnostic platforms, improving accessibility in underserved areas. These efforts, combined with capacity-building programmes for oncology specialists, create a foundation for long-term neuro-oncology market growth in emerging economies.
Key Benefits for Stakeholders
- The report offers a quantitative assessment of market segments, emerging trends, projections, and market dynamics for the period 2024 to 2035.
- The report presents comprehensive market research, including insights into key growth drivers, challenges, and potential opportunities.
- Porter's Five Forces analysis evaluates the influence of buyers and suppliers, helping stakeholders make strategic, profit-driven decisions and strengthen their supplier-buyer relationships.
- A detailed examination of market segmentation helps identify existing and emerging opportunities.
- Key countries within each region are analysed based on their revenue contributions to the overall market.
- The positioning of market players enables effective benchmarking and provides clarity on their current standing within the industry.
- The report covers regional and global market trends, major players, key segments, application areas, and strategies for market expansion.
Frequently Asked Question(FAQ) :
The Primary Brain Tumor segment is the market leader, accounting for 58.4% of the global revenue share in 2024. This dominance is driven by the rising incidence of gliomas and meningiomas, alongside increased adoption of early diagnostic screening.
Magnetic Resonance Imaging (MRI) is the leading diagnostic modality, capturing a 34.9% market share in 2024. Its high-resolution, non-invasive capabilities make it indispensable for surgical planning and treatment monitoring.
Surgery remains the frontline treatment and the largest revenue contributor, holding a 36.7% market share in 2024. Growth in this segment is supported by advancements in minimally invasive techniques and neuronavigation systems.
North America dominates the global market with a 40.01% revenue share as of 2024. This leadership is attributed to cutting-edge healthcare infrastructure, a robust clinical trial network, and favorable reimbursement frameworks.
The Asia-Pacific region is identified as the fastest-growing market, with a projected CAGR of 8.7%. This growth is fueled by expanding healthcare infrastructure, government-led cancer screening initiatives, and rising awareness in countries like China, India, and Japan.
AI is transforming the market through powered imaging algorithms that improve early detection accuracy and automated tumor segmentation. Notable developments include GE HealthCare’s acquisition of MIM Software to enhance AI-powered imaging analytics for oncology.
The adoption of advanced treatments in low- and middle-income countries is hindered by high procedural costs, weak reimbursement policies, and limited healthcare infrastructure, such as the uneven distribution of specialist oncology centers.
Key players include Merck & Co., Siemens Healthineers, and GE HealthCare. Significant recent moves include AstraZeneca’s acquisition of Fusion Pharmaceuticals to strengthen its precision oncology pipeline and GE HealthCare’s acquisition of MIM Software.
TTFields are a non-invasive treatment modality for aggressive tumors like glioblastoma. In February 2024, the U.S. FDA expanded its approved indications, and recent partnerships (such as Novocure and Roche) are evaluating its use in combination with immunotherapy.
